Corrigendum to“Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca^(2+)/CaMKII pathway”[J.Pharm.Anal.14(2024)435–438]  

作　　者：Congyu Ma Ning Sheng Jun Wu Lulu Wang Jiandong Jiang Haibo Yu Jinlan Zhang 

机构地区：[1]State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China [2]Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100050,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第6期933-933,共1页药物分析学报（英文版）

摘　　要：The authors regret there was an unfortunate error in the reproduction of Fig.1I in the article.In the original figure,the fluorescence picture of the positive control drug-ifenprodil was misused.The authors have corrected Fig.1I and provided the original fluorescence pictures of all groups(seven groups,n=5 for each group)to the editorial office.Below,the corrected Fig.1I is shown below.The authors declare that this correction does not affect the description,interpretation,or the original conclusions of the article.

关 键 词：correction Active PICTURE 

分 类 号：R285.5[医药卫生—中药学]